-
-737.jpg)
Our MissionCare for Life, Dedicate to Innovation -
Our VisionDevelop High Quality Medicines to Meet Medical Needs of Patients -
Our Core ValuesExcellence, Persistence, Integrity, Collaboration
Who we are
Rooted in China, innovate for Global
Established since 2019 in Shanghai, China, LaNova Medicines has emerged as a clinical-stage biotechnology company committed to discovering and developing innovative biologic drugs that transform cancer treatments. Our leadership team, composed of experienced industry experts with an unwavering passion for innovation, drives our R&D prowess to deliver transformative therapies for the unmet medical needs of cancer patients.
Harnessing our state-of-the-art technology platforms and deep insight of the tumor microenvironment, we have meticulously crafted a differentiated product pipeline. At LaNova Medicines, we work tirelessly to advance our programs into the clinical domain, with the goal of redefining the treatment landscape of life-threatening diseases.
Our Science
Robust R&D platforms powered by proprietary technologies
LaNova Medicines specializes in antibody discovery, particularly focusing on multi-transmembrane protein targets like GPCRs. Our R&D team has vast expertise covering target validation, antibody engineering, biologics production, translational studies and clinical development. Leveraging our deep knowledge in antibody discovery, we have built robust R&D platforms to fuel innovation and position us at the forefront of biotech advancements.
-
LX-TAb™
Our targeted antibody discovery platform creates antibodies for various targets including multi-transmembrane proteins, and provides three important benefits: greater screening efficiency, quicker development, and improved druggability.
Learn More
-
LX-ADC™
Our next-generation ADC platform delivers transformative targeted therapies by combining creative target selection, customized antibody, and LaNova's proprietary linker-payloads.
Learn More
-
LX-TDuo™
Our proprietary T-cell engager platform generates multi-specific antibodies to specifically activate immune cells in the tumor microenvironment, aiding in the eradication of cancer cells.
Learn More
Pipeline
Innovative programs targeting the tumor microenvironment
At LaNova, we adopt a comprehensive approach to tackle the complex challenges inherent in cancer treatment. Harnessing the power of our R&D platforms, we have devised a diverse array of therapeutics with varied targets and modalities, effectively influencing the tumor microenvironment. Our robust pipeline encompasses both clinical and preclinical stage programs, addressing a wide range of high-value indications in solid tumors and hematological malignancies.
We take immense pride in the unique differentiation and exclusive intellectual property rights of our internally discovered, trailblazing programs. Our unwavering dedication to innovation and excellence propels us forward in our quest to transform the therapeutic landscape and improve the lives of those affected by cancer.
(BMS-986476)
(BMS-986476)
Partnerships
Creating long-lasting strategic alliances for innovation
Innovation and collaboration lie at the heart of LaNova’s guiding principles. We enthusiastically invite partners who share our vision to engage in product- or technology-focused collaborations with us. We are flexible with different collaboration models, including out-license, in-license, co-development, etc.. Our objective is to cultivate fruitful partnerships that capitalize on the distinct expertise of each party and fully realize the potential of our innovative products.
Press Center
Latest News
-91.jpg)
-
2022-11-15
LaNova Medicines Announces the IND Approval of LM-101 by NMPA
Shanghai November 15th, 2022 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-101, an anti-SIRPα monoclonal antibody, has been approved by China NMPA.
Learn More
-
2022-11-10
LaNova Medicines Announces the IND Approval of LM-305, a GPRC5D-targeting ADC Drug by NMPA
Shanghai November 10th, 2022 – LaNova Medicines Ltd. announces that the investigational new drug (IND) of LM-305, an ADC drug targeting GPRC5D, has been approved by China NMPA.
Learn More
-
2021-12-23
LM-108 Submitted US FDA Clinical Trial Application
CCR8 antibody LM-108 submitted US FDA clinical study application in December 2021. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-108.
Learn More
Join Us
To deliver transformative therapeutics for cancer patients
